Disease control of atopic dermatitis in people receiving dupilumab treatment: a plain language summary of the real-world study on Atopic Dermatitis Control Tool in the Gulf countries

Plain Language SummaryWhat is this summary about?This summary describes the results of a study in the Gulf countries. This study assessed how well dupilumab treatment controls atopic dermatitis, how people with atopic dermatitis respond to treatment with dupilumab, and their satisfaction levels to the treatment over a period of 24 weeks.Atopic dermatitis, commonly known as eczema, is a chronic (long-lasting) inflammatory condition that causes red inflamed patches and dry itchy skin. Atopic Dermatitis Control Tool (ADCT) is a questionnaire that was filled by the study participants, and it helps doctors to understand how well atopic dermatitis is being controlled. This tool tracks the changes in the condition of a person over time. ADCT provides the people with atopic dermatitis the opportunity to actively assess and communicate their perception of the disease status.Dupilumab is an advanced treatment option that helps in reducing systemic and skin inflammation in atopic dermatitis. Even though there is reduction in skin flares, people with atopic dermatitis may still experience continuous itch, and sleep problems, making it necessary to focus on its long-term control.This study involved 187 people with atopic dermatitis (aged 12 to 82 years) from the Gulf countries (Saudi Arabia, the United Arab Emirates [UAE], and Kuwait).What were the results?The results from this study revealed that treatment with dupilumab substantially improved disease control over time in people with moderate-to-severe atopic dermatitis. After treatment with dupilumab for 24 weeks, approximately 75% of the people reported controlled disease and almost all reported improved disease control.Disease severity reduced drastically after initiating treatment compared to the severity when the study began. Many people rated their treatment as ‘very good’ or ‘excellent’. People with atopic dermatitis also felt a positive impact on their daily life due to reduced number of doctor visits and a smaller number of missed work/ school days. Most of the side effects reported in the study were considered mild-to-moderate in severity.What do the results mean?Dupilumab was effective in treatment of people with moderate-to-severe atopic dermatitis from the Gulf countries. The people with atopic dermatitis showed improvements in disease control and had less severe symptoms as well as better patient satisfaction. International guidelines recommend dupilumab as the first choice for people with atopic dermatitis when topical treatments don’t work. This is the first real-world data from the Gulf region that provides evidence to support dupilumab use for treating moderate-to-severe atopic dermatitis.How to say (download PDF and double click sound icon to play sound)…Atopic dermatitis: ay-TOP-ik der-muh-TY-tisDupilumab: doo-PIL-yoo-mabInflammation: in-fluh-MAY-shunGenetic predisposition: juh-NET-ik pree-dis-puh-ZISH-unEczema: A common inflammatory disease that causes the skin to become red, itchy, and uncomfortable.Inflammation: Inflammation is the body’s natural response to protect itself when something harmful affects it. Signs may include redness, swelling, warmth, pain or discomfort. When there is an injury or infection, the body sends extra blood and immune cells to the area to help fight infection and improve healing.Systemic inflammation: When the inflammatory response spreads throughout the body, affecting multiple organs and systems, it is called systemic inflammation.Real-world study: A real-world study is a way of looking at how treatments actually work in everyday life, instead of in a controlled laboratory or hospital setting.This is an abstract of the Plain Language Summary of Publication article.